Dianthus Therapeutics (NASDAQ:DNTH) Raised to Strong-Buy at Raymond James Financial

Dianthus Therapeutics (NASDAQ:DNTH) was upgraded by investment analysts at Raymond James Financial from an “outperform” rating to a “strong-buy” rating in a research note issued on Tuesday,Benzinga reports. The firm presently has a $123.00 price target on the stock, up from their prior price target of $63.00. Raymond James Financial’s price objective points to a potential upside of 55.24% from the company’s previous close.

A number of other equities analysts have also issued reports on the stock. Jefferies Financial Group set a $98.00 target price on shares of Dianthus Therapeutics and gave the company a “buy” rating in a research report on Monday. Stifel Nicolaus set a $120.00 price objective on Dianthus Therapeutics in a report on Monday. Robert W. Baird raised their price objective on shares of Dianthus Therapeutics from $67.00 to $132.00 and gave the company an “outperform” rating in a research report on Tuesday. TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a research report on Monday. Finally, Wedbush lifted their price target on Dianthus Therapeutics from $55.00 to $80.00 and gave the stock an “outperform” rating in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $115.33.

Dianthus Therapeutics Stock Up 21.5%

NASDAQ:DNTH opened at $79.23 on Tuesday. The company has a market cap of $3.42 billion, a PE ratio of -22.77 and a beta of 1.56. Dianthus Therapeutics has a 52 week low of $13.36 and a 52 week high of $84.86. The business’s 50 day moving average is $49.17 and its two-hundred day moving average is $41.17.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Monday, March 9th. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.46). The business had revenue of $0.57 million during the quarter, compared to analyst estimates of $0.40 million. Dianthus Therapeutics had a negative net margin of 4,106.04% and a negative return on equity of 33.02%. As a group, sell-side analysts expect that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Dianthus Therapeutics by 4.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock valued at $280,000 after acquiring an additional 618 shares in the last quarter. Ensign Peak Advisors Inc acquired a new position in Dianthus Therapeutics in the second quarter worth $2,504,000. American Century Companies Inc. raised its holdings in shares of Dianthus Therapeutics by 13.2% in the second quarter. American Century Companies Inc. now owns 54,140 shares of the company’s stock valued at $1,009,000 after buying an additional 6,323 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of Dianthus Therapeutics during the second quarter worth approximately $503,000. Finally, Sio Capital Management LLC raised its position in Dianthus Therapeutics by 101.8% in the 2nd quarter. Sio Capital Management LLC now owns 236,070 shares of the company’s stock worth $4,398,000 after purchasing an additional 119,073 shares during the last quarter. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Dianthus Therapeutics

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Early “GO” decision for the Phase 3 CAPTIVATE CIDP trial — the company reported it met the Part A responder criteria (20 confirmed responders with fewer than 40 completers) and will keep the 300mg S.C. dose while engaging regulators to remove the 600mg dose, accelerating the program toward the planned next steps. Early GO Decision Press Release
• Positive Sentiment: Multiple analyst upgrades and higher price targets have lifted sentiment and helped push DNTH to a new 12‑month high; this analyst momentum supports further upside expectations. Analyst Upgrade / 12-Month High
• Neutral Sentiment: Company hosted / scheduled a conference call and webcast to discuss the interim responder analysis (transcript and slides available) — useful for investors seeking detail on responder definitions and next steps but not new data beyond the GO decision. Conference Call / Webcast Notice
• Neutral Sentiment: Short interest data reported appears negligible/zero and does not presently signal a material short pressure or squeeze dynamic. (Entry data showed 0 shares short, 0.0 days to cover.)
• Negative Sentiment: Proposed $400 million underwritten public offering — the company announced a sizable equity raise (with a 30‑day option to upsize by $60M), which can be dilutive and likely caps near‑term upside until proceeds are deployed. Public Offering Announcement
• Negative Sentiment: Q4 earnings miss — DNTH reported a larger-than-expected GAAP loss (EPS -$1.43 vs. consensus -$0.97); while revenue beat nominally, the wider loss underscores current cash burn and execution risks. Q4 Results / Earnings Miss
• Negative Sentiment: New AI/cyber/privacy risk disclosure — the company flagged heightened cyber, privacy and reputational risks related to AI integration, a cautionary corporate‑governance/regulatory risk that could increase compliance costs or negative headlines. AI / Cyber Risk Disclosure

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.